Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1900797 | 0.86 | GRM5 (1.00) | GRM5ALDH1A1MEN1KMT2AHTR1A | |
| SCHEMBL1902638 | 0.84 | GRM5 (1.00) | GRM5ALDH1A1 | |
| SCHEMBL27736419 | 0.82 | GRM5 (0.75) | GRM5ALDH1A1MEN1KMT2A | |
| SCHEMBL12670034 | 0.81 | GRM5 (0.82) | GRM5ALDH1A1 | |
| SCHEMBL1903623 | 0.81 | GRM5 (0.77) | GRM5ALDH1A1MEN1KMT2A | |
| SCHEMBL1902051 | 0.79 | GRM5 (0.74) | GRM5ALDH1A1 | |
| SCHEMBL1906328 | 0.79 | GRM5 (1.00) | GRM5MEN1KMT2AHTR1AHTR7 | |
| SCHEMBL1904972 | 0.76 | GRM5 (0.82) | GRM5ALDH1A1 | |
| SCHEMBL1902972 | 0.76 | GRM5 (1.00) | GRM5ALDH1A1 | |
| SCHEMBL1907979 | 0.75 | GRM5 (1.00) | GRM5MEN1KMT2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935703-B2 | Piperazines and piperidines as Mglur5 potentiators | ASTRAZENECA AB (SE) | 2011-05-03 | — | — | US | claimed |
| EP-1979320-B1 | PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | claimed |
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | claimed |
| US-7935703-B2 | Piperazines and piperidines as Mglur5 potentiators | ASTRAZENECA AB (SE) | 2011-05-03 | — | — | US | disclosed |
| EP-1979320-B1 | PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | GRM5, GRM1, GRIN1 | GRM5 1/4885ALDH1A1 1480/4885MEN1 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.